Evidence map›Paper›PMID 37592321›Full record

ArticleStem cell research & therapy2023

Efferocytosis of viable versus heat-inactivated MSC induces human monocytes to distinct immunosuppressive phenotypes.

Michael V Schrodt, Riley M Behan-Bush, Jesse N Liszewski, Madeleine E Humpal-Pash, Lauren K Boland, Sabrina M Scroggins, Donna A Santillan, James A Ankrum

Open access · goldAbstract read
In one paragraph

Article in Stem cell research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Michael V SchrodtRoy J. Carver Department of Biomedical Engineering, University of Iowa, Iowa City, IA, 52245, USA.
Riley M Behan-BushRoy J. Carver Department of Biomedical Engineering, University of Iowa, Iowa City, IA, 52245, USA.
Jesse N LiszewskiRoy J. Carver Department of Biomedical Engineering, University of Iowa, Iowa City, IA, 52245, USA.
Madeleine E Humpal-PashRoy J. Carver Department of Biomedical Engineering, University of Iowa, Iowa City, IA, 52245, USA.
Lauren K BolandRoy J. Carver Department of Biomedical Engineering, University of Iowa, Iowa City, IA, 52245, USA.
Sabrina M ScrogginsDepartment of Obstetrics and Gynecology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
Donna A SantillanDepartment of Obstetrics and Gynecology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA.
James A AnkrumRoy J. Carver Department of Biomedical Engineering, University of Iowa, Iowa City, IA, 52245, USA. james-ankrum@uiowa.edu.ORCID http://orcid.org/0000-0003-3959-6158
University of Iowa · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Michael J Goodheart · 2000 to 2026
$70.0M
Training CoreP42ES013661 · NIEHS · UNIVERSITY OF IOWA · PI KAI WANG · 2006 to 2026
$60.3M
Medical Scientist Training ProgramT32GM139776 · NIGMS · UNIVERSITY OF IOWA · PI Gordon F Buchanan · 2021 to 2026
$6.4M
Testing the efficacy of regulatory dendritic cell treatment in the prevention of preeclampsiaK01HL155240 · NHLBI · UNIVERSITY OF MINNESOTA · PI SCROGGINS, SABRINA MARIE · 2021 to 2025
$751k
NCI NIH HHS P30 CA086862NHLBI NIH HHS K01 HL155240NIEHS NIH HHS P42 ES013661NIGMS NIH HHS T32 GM139776
6 · The paper itself

Abstract

backgroundImmunomodulation by mesenchymal stromal cells (MSCs) can occur through trophic factor mechanisms, however, intravenously infused MSCs are rapidly cleared from the body yet a potent immunotherapeutic response is still observed. Recent work suggests that monocytes contribute to the clearance of MSCs via efferocytosis, the body's natural mechanism for clearing dead and dying cells in a non-inflammatory manner. This begs the questions of how variations in MSC quality affect monocyte phenotype and if viable MSCs are even needed to elicit an immunosuppressive response.

methodsHerein, we sought to dissect MSC's trophic mechanism from their efferocytic mechanisms and determine if the viability of MSCs prior to efferocytosis influences the resultant phenotype of monocytes. We cultured viable or heat-inactivated human umbilical cord MSCs with human peripheral blood mononuclear cells for 24 h and observed changes in monocyte surface marker expression and secretion profile. To isolate the effect of efferocytosis from MSC trophic factors, we used cell separation techniques to remove non-efferocytosed MSCs before challenging monocytes to suppress T-cells or respond to inflammatory stimuli. For all experiments, viable and heat-inactivated efferocytic-licensing of monocytes were compared to non-efferocytic-licensing control.

resultsWe found that monocytes efferocytose viable and heat-inactivated MSCs equally, but only viable MSC-licensed monocytes suppress activated T-cells and suppression occurred even after depletion of residual MSCs. This provides direct evidence that monocytes that efferocytose viable MSCs are immunosuppressive. Further characterization of monocytes after efferocytosis showed that uptake of viable-but not heat inactivated-MSC resulted in monocytes secreting IL-10 and producing kynurenine. When monocytes were challenged with LPS, IL-2, and IFN-γ to simulate sepsis, monocytes that had efferocytosed viable MSC had higher levels of IDO while monocytes that efferocytosed heat inactivated-MSCs produced the lowest levels of TNF-α.

conclusionCollectively, these studies show that the quality of MSCs efferocytosed by monocytes polarize monocytes toward distinctive immunosuppressive phenotypes and highlights the need to tailor MSC therapies for specific indications.

Indexed as

Leukocytes, MononuclearMonocytesBiological TransportHumansImmunosuppressive AgentsPhagocytosisPhenotypeImmunosuppressive AgentsCell therapyEfferocytosisHeat-inactivationImmunomodulatoryMesenchymal stem cellMesenchymal stromal cellMonocytesSepsisT-cells

Identifiers

PMID37592321
PMCPMC10433682
OpenAlexW4385953812

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.